profit from every SEK 100 of sales.
SEK 0SEK 100
RaySearch Laboratories
SEK 179.30+1.88% today
-17.8% in 1 year
1-year low SEK 164.401-year high SEK 234.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay SEK 26.20 for every SEK 1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What RaySearch Laboratories sold, what it kept, and what it did with the cash.
Sales went from SEK 844 million in 2022 to SEK 1.34 billion in 2025, with SEK 228 million of profit last year.
SalesProfit
RaySearch Laboratories handed back 65% of the cash it generated last year.
SEK 103M
Free cash flow 2025SEK 159M
Bought back its own shares–
Paid as dividendsSEK 103M
Cash vs. debtSEK 407M vs. SEK 395M
RaySearch Laboratories vs. similar companies
RaySearch Laboratories grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| RaySearch Laboratories | 26.2× · Fair price | ||
 Veeva Systems | 53.7× · Expensive | ||
 Pro Medicus | 183.7× · Very expensive | ||
 Hinge Health | No profit yet | ||
 M3 | 30.1× · Expensive |
AI analysis
An AI analyst reads RaySearch Laboratories's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 844 | 1,022 | 1,192 | 1,344 | |
| 749 | 916 | 1,093 | 1,242 | |
| 30 | 122 | 251 | 330 | |
| 341 | 406 | 571 | 587 | |
| 24 | 82 | 204 | 228 | |
| 0.69 | 2.38 | 5.94 | 6.65 | |
| 88.7% | 89.6% | 91.7% | 92.4% | |
| 3.6% | 12.0% | 21.1% | 24.5% | |
| 2.8% | 8.0% | 17.1% | 16.9% |
Balance sheet
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,876 | 1,953 | 2,091 | 1,992 |
| Cash | 160 | 344 | 463 | 407 |
| Total debt | 555 | 529 | 472 | 395 |
| Total liabilities | 1,219 | 1,217 | 1,215 | 1,007 |
| 657 | 735 | 877 | 985 | |
| 34 | 34 | 34 | 34 | |
| 2.9% | 7.5% | 16.0% | 17.0% | |
| 3.6% | 11.1% | 23.2% | 23.1% |
Cash flow
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 321 | 456 | 485 | 387 | |
| 201 | 209 | 218 | 228 | |
| 119 | 247 | 268 | 159 | |
| Dividends paid | – | – | 69 | 103 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 26.2×
- –
- 0.23
- 7.4×
- 4.4×
- 37.6×
- 10.1×
- 2.7%
- 3.8%
- 1.7%
Profitability
- 92.4%
- 24.5%
- 16.9%
- –
- 17.0%
- 10.9%
- –
- –
- –
- –
Growth
- +16.8%
- +112.8%
- –
- –
- +0.0%
Financial health
- -0.0×
- 0.40
- –
- 37.9×
- 1.70
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 952
Top 15%of 884
Top 49%of 601
Top 32%of 886
Top 38%of 987
1.7%of the share price, paid each year
On $1,000 invested$17a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
45.1% of its profit
Room to growStretchedMore than it earns: 64.7%
News
RaySearch Laboratories reports Q3 resultsSeeking Alpha · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
66Pass
Benjamin Graham
50No pass
Philip Fisher
82Pass
Peter Lynch
95Pass
Joel Greenblatt
34No pass
Charlie Munger
64Pass
Terry Smith
56No pass
Questions about RaySearch Laboratories
Is RaySearch Laboratories a good stock to buy?
A solid business at a fair price. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the RaySearch Laboratories AI analysis
What does RaySearch Laboratories do?
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It is in Health Information Services, based in Stockholm, Sweden, with 465 employees.
Does RaySearch Laboratories pay a dividend?
Yes. At today's price the dividend is 1.7% a year, about 45% of its yearly profit. In 2025 it paid out SEK 103 million in dividends.
Is RaySearch Laboratories stock halal?
Yes. RaySearch Laboratories passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has RaySearch Laboratories stock done over the past year?
Down 17.8% over the past twelve months, to SEK 179.30. It traded between SEK 164.40 and SEK 234.00 and is 23.4% below its high.
Who are RaySearch Laboratories's competitors?
The largest listed companies in the same industry are Veeva Systems, Pro Medicus, Hinge Health and M3. The peers table on this page compares their profit, growth and price with RaySearch Laboratories's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.